Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer.

Semin Radiat Oncol 2020 Oct;30(4):273-280

Department of Radiation Medicine and Applied Sciences, UC San Diego, La Jolla, CA. Electronic address:

Outcomes for women with node-positive, recurrent, and metastatic cervical cancer remain poor. Persistent infection by the human papilloma virus is related to disordered interactions with the immune system and development of cervical cancer, making the resultant malignancy an attractive target for immunotherapy. Various types of immunomodulatory treatments have been studied, including a bacterial vaccine vector and T cell therapy. Immune checkpoint blockade has shown promise in the recurrent or metastatic settings, and in combination with chemoradiotherapy for definitive treatment with acceptable toxicity profiles. Ongoing trials are investigating timing, dosing, and combinations of immunomodulatory treatments, with potential to improve survival and advance our understanding of the immune system's role in combating cervical cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semradonc.2020.05.003DOI Listing
October 2020

Publication Analysis

Top Keywords

cervical cancer
16
immunomodulatory treatments
8
recurrent metastatic
8
therapy immune
4
cell therapy
4
immune checkpoint
4
checkpoint blockade
4
settings combination
4
combination chemoradiotherapy
4
metastatic settings
4
promise recurrent
4
blockade promise
4
vector cell
4
bacterial vaccine
4
target immunotherapy
4
attractive target
4
malignancy attractive
4
resultant malignancy
4
immunotherapy types
4
types immunomodulatory
4

Similar Publications